K
Kim Loesch
Researcher at University of Texas Medical Branch
Publications - 3
Citations - 536
Kim Loesch is an academic researcher from University of Texas Medical Branch. The author has contributed to research in topics: Transgene & Hepatitis C virus. The author has an hindex of 2, co-authored 2 publications receiving 529 citations.
Papers
More filters
Journal ArticleDOI
Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.
Hervé Lerat,Masao Honda,Michael R. Beard,Kim Loesch,Jiaren Sun,Yan Yang,Michiari Okuda,Rainer Gosert,Shu-Yuan Xiao,Steven A. Weinman,Stanley M. Lemon +10 more
TL;DR: Constitutive expression of viral proteins leads to common pathologic features of hepatitis C in the absence of specific anti-viral immune responses, while additional low level expression of nonstructural proteins increases the risk of cancer.
Journal ArticleDOI
Impaired Clearance of Virus-Infected Hepatocytes in Transgenic Mice Expressing the Hepatitis C Virus Polyprotein
Olivier Disson,Delphine Haouzi,Solange Desagher,Kim Loesch,Michael Hahne,Eric J. Kremer,Chantal Jacquet,Stanley M. Lemon,Urszula Hibner,Hervé Lerat +9 more
TL;DR: The results suggest that viral evasion of cell-mediated immune responses leading to apoptotic death of hepatocytes may contribute to viral persistence and might also contribute to the development of liver cancer in HCV.
Journal ArticleDOI
Abstract 410: Development of novel, non-toxic rifamycins that reverse drug resistance
Steve Maxwell,Deeann Wallis,Nian Lai Zhou,Dwight Baker,Seyed Hossein Mousavi-Fard,Kim Loesch,Stacy Galaviz,Liam M. Guthrie,Thomas Snavely,Qingan Sun,Carolina Mantilla Rojas,David W. Threadgill,Thomas R. Ioerger,Wen-Juan Dong,Gwen Seemann,Theresa W. Fossum,James C. Sacchettini +16 more
TL;DR: RTI has a broad spectrum of action in both double- and triple-hit DLBCL and synergizes with many different chemotherapeutics to restore drug sensitivity and provides for a broad, safe, and novel approach to treating drug resistant cancers.